New England Research & Management Raised Abbvie (ABBV) Position; RPC, Inc. (RES) Covered By 11 Bullish Analysts Last Week

June 19, 2017 - By Marie Mckinney

New England Research & Management Inc increased Abbvie Inc. (ABBV) stake by 129.99% reported in 2016Q4 SEC filing. New England Research & Management Inc acquired 4,950 shares as Abbvie Inc. (ABBV)’s stock rose 6.17%. The New England Research & Management Inc holds 8,758 shares with $548,000 value, up from 3,808 last quarter. Abbvie Inc. now has $114.49 billion valuation. The stock rose 0.61% or $0.43 reaching $71.48 per share. About 773,268 shares traded. AbbVie Inc (NYSE:ABBV) has risen 10.63% since June 19, 2016 and is uptrending. It has underperformed by 6.07% the S&P500.

Among 18 analysts covering RPC (NYSE:RES), 11 have Buy rating, 0 Sell and 7 Hold. Therefore 61% are positive. RPC had 45 analyst reports since August 14, 2015 according to SRatingsIntel. On Wednesday, January 6 the stock rating was upgraded by FBR Capital to “Outperform”. The stock of RPC, Inc. (NYSE:RES) earned “Market Perform” rating by FBR Capital on Monday, September 21. The company was maintained on Thursday, April 28 by Cowen & Co. The rating was downgraded by Seaport Global on Tuesday, April 19 to “Reduce”. The firm has “Buy” rating given on Wednesday, January 18 by Suntrust Robinson. The stock has “Buy” rating by Jefferies on Friday, April 7. On Monday, November 28 the stock rating was initiated by Jefferies with “Buy”. Tudor Pickering upgraded the stock to “Buy” rating in Tuesday, January 12 report. Morgan Stanley upgraded the shares of RES in report on Thursday, January 28 to “Overweight” rating. Goldman Sachs downgraded RPC, Inc. (NYSE:RES) rating on Friday, March 11. Goldman Sachs has “Neutral” rating and $15 target. See RPC, Inc. (NYSE:RES) latest ratings:

13/04/2017 Broker: BMO Capital Markets Rating: Outperform New Target: $24.00 Initiates Coverage On
07/04/2017 Broker: Jefferies Rating: Buy New Target: $26.00 Maintain
24/03/2017 Broker: Tudor Pickering Rating: Buy Initiate
22/02/2017 Broker: Susquehanna Rating: Neutral New Target: $23 Initiate
26/01/2017 Broker: Credit Suisse Old Rating: Neutral New Rating: Outperform Upgrade
26/01/2017 Broker: Guggenheim Old Rating: Neutral New Rating: Buy Upgrade
19/01/2017 Broker: Cowen & Co Old Rating: Outperform New Rating: Market Perform New Target: $20 Downgrade
18/01/2017 Broker: Suntrust Robinson Rating: Buy Initiate
18/01/2017 Broker: SunTrust Rating: Buy Initiate
17/01/2017 Broker: Nomura Old Rating: Neutral New Rating: Buy Upgrade

Among 18 analysts covering Abbvie Inc (NYSE:ABBV), 7 have Buy rating, 1 Sell and 10 Hold. Therefore 39% are positive. Abbvie Inc had 37 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of AbbVie Inc (NYSE:ABBV) earned “Market Perform” rating by Cowen & Co on Monday, June 6. The firm has “Hold” rating by BMO Capital Markets given on Wednesday, April 19. The firm earned “Neutral” rating on Thursday, September 8 by JP Morgan. Credit Suisse downgraded the shares of ABBV in report on Monday, October 31 to “Neutral” rating. The company was downgraded on Friday, June 10 by BMO Capital Markets. The stock of AbbVie Inc (NYSE:ABBV) has “Mkt Perform” rating given on Tuesday, October 18 by Leerink Swann. Barclays Capital downgraded it to “Equal-Weight” rating and $72 target in Tuesday, December 1 report. The stock of AbbVie Inc (NYSE:ABBV) has “Overweight” rating given on Monday, November 2 by Morgan Stanley. BMO Capital Markets maintained AbbVie Inc (NYSE:ABBV) on Friday, April 28 with “Hold” rating. The firm has “Buy” rating by Citigroup given on Tuesday, February 23.

New England Research & Management Inc decreased Celgene (NASDAQ:CELG) stake by 3,480 shares to 11,275 valued at $1.31 million in 2016Q4. It also reduced Headwaters Inc (NYSE:HW) stake by 16,431 shares and now owns 50,106 shares. Rollins (NYSE:ROL) was reduced too.

Investors sentiment decreased to 0.98 in Q4 2016. Its down 0.05, from 1.03 in 2016Q3. It dropped, as 86 investors sold ABBV shares while 555 reduced holdings. 99 funds opened positions while 531 raised stakes. 1.03 billion shares or 0.70% less from 1.04 billion shares in 2016Q3 were reported. Braun Stacey Assoc reported 212,532 shares. Omers Administration reported 9,600 shares stake. Evergreen Capital Limited Liability has 4,129 shares for 0.05% of their portfolio. Gilman Hill Asset Limited Liability Co holds 0.33% of its portfolio in AbbVie Inc (NYSE:ABBV) for 14,326 shares. The Delaware-based Dupont Cap Management has invested 0.14% in AbbVie Inc (NYSE:ABBV). Lathrop Invest Mgmt holds 6,394 shares. Livingston Group Asset Mngmt (Operating As Southport Management) owns 13,877 shares or 0.53% of their US portfolio. Moreover, Foster & Motley Inc has 0.47% invested in AbbVie Inc (NYSE:ABBV) for 39,359 shares. The United Kingdom-based Aberdeen Asset Management Public Limited Company Uk has invested 0.19% in AbbVie Inc (NYSE:ABBV). Indiana Tru Investment Company has invested 0.68% in AbbVie Inc (NYSE:ABBV). 14,924 are held by West Oak Cap. 56,422 were accumulated by Conning. Shoker Inv Counsel Inc accumulated 25,984 shares. Beaumont Fincl Prns Limited Liability Com holds 0.05% or 5,032 shares in its portfolio. Raymond James Trust Na holds 0.78% of its portfolio in AbbVie Inc (NYSE:ABBV) for 156,732 shares.

Since February 28, 2017, it had 0 buys, and 10 selling transactions for $28.02 million activity. $5.59M worth of AbbVie Inc (NYSE:ABBV) was sold by Schumacher Laura J. Shares for $2.50M were sold by CHASE WILLIAM J on Thursday, May 18. The insider ALBAN CARLOS sold 45,800 shares worth $3.21 million. RICHMOND TIMOTHY J. had sold 22,451 shares worth $1.47 million on Friday, March 10. HURWICH THOMAS A. sold $143,031 worth of stock or 2,311 shares. The insider Michael Robert A. sold $335,068. GONZALEZ RICHARD A also sold $4.67M worth of AbbVie Inc (NYSE:ABBV) shares.

Investors sentiment increased to 1.16 in 2016 Q4. Its up 0.03, from 1.13 in 2016Q3. It improved, as 16 investors sold RPC, Inc. shares while 70 reduced holdings. 44 funds opened positions while 56 raised stakes. 78.17 million shares or 0.49% more from 77.79 million shares in 2016Q3 were reported. Winfield Assocs invested in 0% or 170 shares. Herndon Capital Management Llc reported 62 shares or 0% of all its holdings. Northern Tru has invested 0% in RPC, Inc. (NYSE:RES). Raymond James And Associate has invested 0% of its portfolio in RPC, Inc. (NYSE:RES). Riverhead Management Limited Liability accumulated 4,300 shares or 0.01% of the stock. Hanson Mcclain holds 0% of its portfolio in RPC, Inc. (NYSE:RES) for 1,125 shares. Employees Retirement Association Of Colorado owns 1,872 shares for 0% of their portfolio. Waddell & Reed holds 0.16% in RPC, Inc. (NYSE:RES) or 3.73 million shares. Lord Abbett & Limited Liability Co has 77,000 shares. Independent Portfolio Consultants Inc owns 7,955 shares for 0.05% of their portfolio. Dimensional Fund Advisors Ltd Partnership owns 1.52M shares for 0.02% of their portfolio. Susquehanna Group Inc Ltd Liability Partnership holds 0% of its portfolio in RPC, Inc. (NYSE:RES) for 79,174 shares. Bank & Trust Of Montreal Can reported 0.01% in RPC, Inc. (NYSE:RES). New York-based National Bank & Trust Of Ny Mellon has invested 0.01% in RPC, Inc. (NYSE:RES). Point72 Asset Mngmt L P reported 0.07% in RPC, Inc. (NYSE:RES).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News